Evaluation of the Clinical Impact of Different Telemedicine Practices in Intensive Care Units
NCT ID: NCT05960994
Last Updated: 2023-10-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
25000 participants
INTERVENTIONAL
2023-11-01
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study provides for the implementation of three interventions in association via telemedicine.
* Daily multidisciplinary rounds conducted by a physician specialized in intensive care medicine
* Intervention package by specialized multidisciplinary team (nursing, physiotherapy and clinical pharmacy).
* Management intervention package (quality and safety).
The main questions it aims to answer are:
* Length of stay in ICU, measured in days, considering the time interval between admission to the ICU and the moment of physical transfer of the patient to another hospital admission area or external transfer.
* ICU mortality.
* Mechanical ventilation free time at 28 days.
* Ventilator-associated events.
* Patient Mobilization Density.
* Standard resource use.
* Standardized mortality rate.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Mechanical Insufflation-exsufflation on Airway Mucus Clearance in the ICU
NCT03178565
Sleep Quality in Intensive Care Unit Patients at High Risk of Extubation Failure
NCT02911506
The Role of Off-shift Robotic Telerounding Between Physicians and Nurses in the Surgical Intensive Care Unit
NCT01576614
Technology-Assisted Early Mobilization Program Among Patients in the Intensive Care Units
NCT06700694
Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure
NCT04632602
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ICU beds represent a scarce and high cost resource. This scenario is aggravated by the scarcity and heterogeneous distribution of specialists in intensive care medicine in Brazil. Telemedicine is an innovative and promising technology, with the possibility of making the daily multidisciplinary round accessible with the presence of intensive care medicine specialists throughout the national territory. In a previous study (Telescope Trial I), it was demonstrated that daily multidisciplinary round conducted via telemedicine by a remotely located medical specialist is a safe and feasible practice. However, little is known about different modalities of telemedicine care in the ICU environment, more specifically, about the impact of interventions performed by a multidisciplinary team (non-medical) and management interventions (quality and safety).
SAMPLE SIZE CALCULATION:
A total sample size of 18,750 to 25,000 patients will be considered to detect a reduction in the length of stay in the ICU on a logarithmic scale of 0.1479 (equivalent to a 1.1-day reduction compared to the baseline), resulting from the intervention package with a significance level of 5% and a minimum power of 95%. This variation in total sample size is due to different estimates of patients per period in the 25 Brazilian ICUs in question. It is estimated that there will be a variation of 30 to 40 patients recruited per month per ICU.
PRIMARY OUTCOME:
Length of stay in the ICU, measured in days, considering the time interval between admission to the ICU and the moment of physical transfer of the patient to another hospital admission area or external transfer.
SECONDARY OUTCOMES:
* ICU mortality.
* Mechanical ventilation free time in 28 days.
* Ventilator-associated events.
* Patient Mobilization Density.
* Standard resource use.
* Standardized mortality rate.
EXPLORATORY OUTCOMES:
* In-hospital mortality.
* Adherence to elevated bedside.
* Adequate prevention of venous thromboembolism.
* Accidental extubation rate.
* Rate of patients with adequate glycemic control (defined as blood glucose \<70mg/dl to \>180mg/dl).
* Rate of patients - day receiving oral or enteral diet.
* Rate of patient-day under adequate sedation \[defined by Richmond agitation and sedation scale (RASS) = -3 to +\].
* Rate of patients on oxygen therapy in normoxia \[defined as peripheral oxygen saturation (SpO2) ≤92% to ≥96%\].
* Rate of ICU readmission within 48 hours.
* Rate of early reintubation (\<48h after extubation).
* Rate of central venous catheter use.
* Rate of indwelling urinary catheter use.
* Central venous catheter use time.
* Time of indwelling urinary catheter use.
STATISTICAL ANALYSIS:
All analyses will be described in detail in a statistical analysis plan, which will be finalized and submitted for publication before the database is closed and analyses begin. The primary statistical analyses will be conducted according to the intention-to-treat principle. Since ICUs will be randomized (not patients) and outcomes will be measured at the patient level, all analyses will be adjusted for clustering of data.
The primary outcome, length of ICU stay, will be analyzed at the individual level using a generalized linear mixed model, including as fixed effect the group, and considering distributions that can fit an expected right skewness (such as truncated Poisson, Gamma or inverse Gaussian distribution, etc.), choosing the best fit according to model parameters. The goal of the mixed model is to be able to fit random vectors, taking into account the correlation of the observations of individuals in the same cluster. Thus, the model will have as random effect an intercept for each unit. To consider an eventual lack of balance, we will adjust the analysis model for the factors used in the stratification and for the outcome value at the unit level in the pre-randomization period (i.e., mean length of stay in the ICU of each unit), as suggested by the literature. Additionally, we will adjust for factors that have a correlation with length of stay, aiming to decrease variability between units, thus impacting intra cluster correlation and increasing the power of the study. The adjustment factors will be defined after the pre-randomization period data collection, and reported in a statistical analysis plan, published before closing the study database, as specified above. These factors are about severity (SAPS 3) and clinical or surgical profile. In the event of a significant amount of missing data on the primary endpoint, the analysis will be re-evaluated after using multiple imputation with chained equations, assuming that the data will be missing at random. Data collected during the transition period will not be analyzed for primary, secondary or exploratory endpoints.
Sensitivity analyses and subgroups for the primary outcome:
We will define, a priori, the following subgroups for analysis of the primary outcome:
A - ICU length of stay stratified by clinical vs elective surgical and emergency surgical patients.
B - Length of stay in ICU stratified by three groups (lower, middle and upper thirds) of severity determined by SAPS 3 score.
C - ICU length of stay stratified by mechanically ventilated patients on admission (invasive mechanical ventilation).
Similarly, in all other analyses, generalized linear mixed models will be used. Analyses of the pre-specified secondary outcomes and subgroup analyses will not be adjusted for multiple comparisons, thus should be interpreted as exploratory.
Due to the importance of the SAPS 3 severity score, we will evaluate the calibration of the model with data from the pre-randomization period. If necessary, we will recalibrate the model for the study population.
The significance level for all endpoints will be 0.05. All analyses will be performed with R software (version 4.2.0, the version will be updated at the time of the analysis).
REGULATORY STATUS:
The study will be conducted in accordance with the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Humans Act.
APPROVAL FROM ETHICS AND REGULATORY AUTHORITIES:
The study will be performed according to the national and international guidelines. The Institutional Review Board of the Hospital Israelita Albert Einstein has approved this study (CAAE: 69575123.0.1001.0071). The participating centers will not initiate the study until they have obtained approval from their respective local Institutional Review Boards. The need for informed consent is determined by the Institutional Review Board of each participating center.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence 1
Sequence 1 will consist of a 3-month control period, followed by a 3-month transition period, and finally, a 19-month intervention period. The total duration of sequence 1 will be 25 months.
Intervention period
During the intervention period, three interventions will be implemented through telemedicine.
1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.
Sequence 2
Sequence 2 will consist of a 7-month control period, followed by a 3-month transition period, and finally, a 15-month intervention period. The total duration of sequence 2 will be 25 months.
Intervention period
During the intervention period, three interventions will be implemented through telemedicine.
1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.
Sequence 3
Sequence 3 will consist of a 11-month control period, followed by a 3-month transition period, and finally, a 9-month intervention period. The total duration of sequence 3 will be 25 months.
Intervention period
During the intervention period, three interventions will be implemented through telemedicine.
1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.
Sequence 4
Sequence 4 will consist of a 15-month control period, followed by a 3-month transition period, and finally, a 7-month intervention period. The total duration of sequence 4 will be 25 months.
Intervention period
During the intervention period, three interventions will be implemented through telemedicine.
1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.
Sequence 5
Sequence 5 will consist of a 19-month control period, followed by a 3-month transition period, and finally, a 3-month intervention period. The total duration of sequence 5 will be 25 months.
Intervention period
During the intervention period, three interventions will be implemented through telemedicine.
1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intervention period
During the intervention period, three interventions will be implemented through telemedicine.
1. A daily multidisciplinary round conducted by a physician specialized in intensive care medicine.
2. A intervention package administered by a specialized multidisciplinary team, consisting of nursing, physiotherapy, and clinical pharmacy.
3. A management intervention package will be implemented, with a specific focus on enhancing quality and safety.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Intensive care units with physician and nurses available 24 hours a day and physiotherapist available at least ≥ 18 hours a day.
* Adult patients (≥ 18 years old).
Exclusion Criteria
* Intensive care units already doing audit and feedback with specific planning.
* Dedicated coronary care units/cardiac intensive care units or other specialized units (cardiac surgery, neurological, burned patients).
* Step-down units or semi-intensive cardiac care unit.
* Intensive care units without availability of substitute renal therapy.
* ICU coordinator specialist in intensive care medicine and management training (MBA in Health Management or equivalent).
* Admission for other reasons than medical (e.g., judicial cause, legal reasons, safety reasons).
* Previously included in the TELESCOPE II trial (for the primary outcome analysis).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, Brazil
OTHER_GOV
Hospital Israelita Albert Einstein
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adriano J Pereira, MD, PhD.
Role: STUDY_DIRECTOR
Hospital Israelita Albert Einstein
Renato CF Chaves, MD, MBA.
Role: PRINCIPAL_INVESTIGATOR
Hospital Israelita Albert Einstein
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5535-23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.